Tranexamic acid, Batroxobin and their Combination for spinal surgery

The efficacy and safety of high dose tranexamic acid on blood loss and postoperative recovery after transforaminal posterior lumbar interbody fusion surgery:a double-blinded, placebo-controlled randomized study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024148

Enrollment

Unknown

Registered

2019-06-27

Start date

2018-07-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar degenerative diseases

Interventions

Experimental group:intravenous bolus of TXA 10 mg/kg 15 minutes before skin incision followed by intravenous infusion of 15 mg/kg from operation beginning to skin closure

control group:0.9% normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) aged between 30 to 80 years old; (2) lumbar disk herniation, stenosis, or spondylolisthesis with unilateral radiculopathy; (3) one-level or two-level surgery through transforaminal posterior lumbar interbody fusion.

Exclusion criteria

Exclusion criteria: lumbar fracture, previous spinal surgery, deformities requiring the correction, coagulation disorder, anticoagulants or antiplatelet medications.

Design outcomes

Primary

Measure	Time frame
intraoperative blood loss;	—

Secondary

Measure	Time frame
postoperative drainage;the time for drainage removal;time to go;hospital stay after surgery;postoperative hemoglobin;	—

Countries

China

Contacts

Public ContactYunsheng Ou

ouyunsheng2001@163.com+86 023 89011212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026